Rituximab associated with lower drug discontinuation and disease relapse rates in multiple sclerosis
Rituximab was associated with lower discontinuation rates as compared to other disease-modifying treatments in newly diagnosed patients with relapsing-remitting multiple sclerosis.
Of the 494 patients, 43.5% received an injectable DMT, 17.4% dimethyl fumarate, 3.4% fingolimod, 10.1% natalizumab, 24.3% rituximab, and 1.2% other DMT.
The FDA has granted Breakthrough Therapy designation for fingolimod for the treatment of children and adolescents 10 years of age or older with relapsing multiple sclerosis (MS).
The researchers found that having dietary quality scores in the highest versus the lowest quintile correlated with lower levels of disability.
There was no difference in the composite functional measure (walking control, balance, manual dexterity, postvoid residual urine volume, and visual acuity) between the PTA and sham groups (41.7 vs. 48.7%; odds ratio, 0.75; 95% confidence interval, 0.34 to 1.68; P=0.49).
Children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a
Approximately 80% of patients from the CARE-MS I trial (n=139) and the CARE-MS II trial (n=143) had elected to enter the extension phase of the study.
Data show superiority of Ocrevus compared to Rebif (interferon beta-1a) in significantly reducing disability Progression Independent of Relapse Activity (PIRA) in people with relapsing multiple sclerosis (RMS)
The overall two-year data showed that compared to placebo, Aubagio significantly reduced cortical gray matter volume (CGMV) loss (Aubagio 7mg, P=0.0089; Aubagio 14mg, P=0.0052) and the risk of CDMD conversion.
The mechanism by which glatiramer acetate exerts its therapeutic effect in MS is unknown, however it is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS.
Data showed that a 50nmol/L increase in 25(OH)D correlated with a 39% decreased risk of MS. Specifically, a 43% increased risk of MS was seen in women with 25(OH)D levels <30nmol/L vs. women with levels ≥50nmol/L.
MPR interviewed Dr. John Stoffel to discuss the strategies for diagnosis and management of urinary retention in MS patients, as well as his recommendations for optimal care for these patients.
Delayed-release DMF exerts anti-inflammatory and neuroprotective properties for the treatment of relapsing multiple sclerosis, a disease that often develops in women between the ages of 20 and 40.
The post-hoc analyses found Ocrevus to significantly decrease disease activity and disability progression in patients with RMS and PPMS, as assessed by No Evidence of Progression or Active Disease (NEPAD), a new composite endpoint in MS.
This new software allows patients currently using the electronic BETACONNECT autoinjector to administer Betaseron (interferon beta-1b) to connect their autoinjector to the new myBETAapp through their mobile device or computer.
The Radiance trial included 1,313 relapsing multiple sclerosis (RMS) patients who were administered either 0.5mg or 1mg of oral ozanimod, or weekly intramuscular interferon beta-1a (Avonex) over a 2 year treatment period.
Cheong noted that only 1 patient was non-adherent. There was an increase in patient knowledge scores, from a mean baseline score of 20.14 to 31.67 (P<0.05) by the end of the third appointment.
Among patients with early relapsing multiple sclerosis patients, Ocrevus suppressed >90% of active MRI lesions over 2 years vs. interferon beta-1a.
The majority of patients who relapsed between courses were free of confirmed disability worsening (CDW) in Year 2 and 60% remained free of CDW by Year 6.
Study patients treated with Aubagio 14mg and 7mg had a significantly reduced risk of developing clinically definite MS vs. placebo (P<0.05).
Over 6 months, the researchers said, none of the patients suffered serious side effects from the treatment. In addition, 3 showed symptom improvements within 2 to 8 weeks of their first T-cell infusion.
The researchers found that maternal illness during pregnancy correlated with 2.3-fold increased odds of having mulitple sclerosis.